Las Vegas residents line up overnight for ALDI grand opening
LAS VEGAS (KLAS) — ALDI has arrived in Southern Nevada.
The new store is located at 621 Marks Street in Henderson and it held a grand opening celebration on Thursday, April 24.
ALDI fans started lining up outside the store at 10:30 p.m. the night before. By around 7 a.m., there were close to 200 shoppers in line.
The waiting paid off as the first 100 customers received a gift bag filled with a sampling of ALDI-exclusive products, a commemorative quarter-sized ALDI poker chip to unlock shopping carts, and a mystery gift card as part of the ALDI Golden Ticket giveaway.
Known for helping families save money, up to 36 percent on average grocery bills, ALDI offers a streamlined, no-frills shopping experience that focuses on quality, affordability, and simplicity.
Some of the store's deals included 3 pounds of turkey meat for under $9 and a dozen eggs priced at just $4.50. The store also includes ALDI's unique cart system, which requires shoppers to deposit a quarter to unlock a cart. Once the cart is returned, so is the quarter, a simple system that helps keep prices low by eliminating the need for cart wranglers.
This is just the beginning of ALDI in the valley as the chain also has a store at 2106 W. Craig Road and another on South Rainbow that opens in May.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Michiganders are returning fewer bottles and cans. Why?
GRAND RAPIDS, Mich. (WOOD) — The value of a dime doesn't stretch as far as it did in 1976 when the state's bottle deposit law was initiated, but for many Michiganders, returning beverage containers to get their 10 cents back sure adds up. 'I don't want to throw my pennies and dimes away,' Grand Rapids resident Mildred Griffin said. 'The cost of living is so high right now. You would be a fool to throw away 10 cents.' For Griffin, returning bottles and cans is a way of life. She said it's like getting paid to recycle. She was surprised to learn that fewer people are turning in their bottles to get that dime back. Statewide return rates have fallen to their lowest point. In 2024, just over 70% of bottles and cans were returned. Workers at a number of local markets told News 8 they have seen fewer returns in recent years. At Kingma's Market in Grand Rapids, owner Alan Hartline said the redemption process adds complications to store owners. He said the process, from collecting to sorting, is in serious need of an update. 'It really taxes the supply chain and adds a lot of cost to it for businesses,' he said, 'I think there can be a better way to facilitate it. It should be earth friendly, but perhaps to do it without the cost and as many hoops as the current process today.' Sen. Sean McCann, D-Kalamazoo, also believes there's a need for change, including an expansion. 'Even though we've come off our highs, habits have changed, there's a real ability to still improve our system and make it get better,' he said. McCann reintroduced a bill to modify the bottle return law to include other containers, primarily plastic water bottles. 'I think it's terrible that we have over 2 billion plastic water bottles that don't necessarily get recycled and often get landfilled and are not eligible for the deposit,' he said. He's also pushing for bottles and cans to be returnable anywhere — not just at chains that carry the brands being returned. He said that is part of the reason the rates are dropping. 'Part of the bugaboo is a universal redemption,' he said. 'You buy something at one store (but) you can't take it back to the other store.' For McCann, the goal is to get the issue on the ballot and let the citizens decide. 'This is not something worth giving up on for me,' he said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Insider
2 hours ago
- Business Insider
Aeluma Inc trading resumes
13:06 EDT Aeluma (ALMU) Inc trading resumes Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yahoo
2 hours ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
